A method for reducing body fat content in fish using androgen receptor agonists and uses thereof

Abstract

The application provides a method and application for reducing the body fat content of fish by using an androgen receptor agonist, and relates to the technical field of fish endocrinology. The application achieves the effect of reducing the body fat content of fish by enhancing the activity of the androgen receptor in the androgen signaling pathway of fish, and inhibiting the transcription and expression of key genes for de novo synthesis of fat, so as to obtain fish with reduced fat synthesis. The method for enhancing the activity of the androgen receptor in the androgen signaling pathway of fish is that the fish is caused to ingest an androgen receptor agonist. Through the above method, the body fat content of fish can be effectively intervened and regulated by using the androgen receptor agonist, which is beneficial to improving the quality of fish meat, preventing diseases induced by excessive accumulation of fish fat, and promoting the healthy development of the fishery. The method provided by the application not only reduces the body fat content of fish, but also expands the application range of the androgen receptor agonist, so that the androgen receptor agonist can be used for the regulation of the body fat content of fish as feed or medicine.

Description

Technical Field

[0001] This invention relates to the field of fish endocrinology, and more particularly to a method and application of using androgen receptor agonists to reduce the body fat content of fish. Background Technology

[0002] With global population growth and increasing consumer demand for healthy foods, aquatic products, especially fish, have become an important source of protein. Fish not only contain high-quality protein but also beneficial components such as omega-3 polyunsaturated fatty acids. However, the health of fish directly affects their nutritional value and food safety; therefore, ensuring fish health has become crucial for the sustainable development of fisheries.

[0003] Fish body fat content refers to the proportion of fat in a fish's body. This indicator has a significant impact on the health and growth of fish, and is also an important factor affecting the quality and nutritional value of fish meat. Appropriate body fat content helps fish maintain good physiological condition, improves their adaptability to environmental changes, and is also an important parameter for evaluating the nutritional value of fish. However, inappropriate husbandry practices, such as overfeeding and nutritional imbalances, can lead to excessively high body fat levels in fish, affecting meat quality and reducing the economic benefits of fisheries.

[0004] By monitoring and managing the body fat content of fish, fish welfare can be improved and diseases induced by excessive fat accumulation can be prevented, thereby reducing dependence on antibiotics and other drugs, and promoting the sustainable development of fisheries and environmental protection.

[0005] In view of this, it is necessary to develop an effective method to reduce the body fat content of fish. This is not only of great significance for the prevention and control of fish diseases, but also key to promoting the fishery industry towards a healthier and more efficient development. Summary of the Invention

[0006] To address the shortcomings of the existing technology, the present invention aims to provide a method and application for reducing body fat content in fish using androgen receptor agonists. Androgen receptors (Ar) are members of the steroid hormone receptor superfamily and the nuclear receptor superfamily, functioning as ligand-activated transcription factors. Currently, research on fish adipogenesis lacks methods for inhibiting body fat content in fish using androgen receptors. This invention utilizes androgen receptor agonists to enhance the activity of androgen receptors in the fish androgen signaling pathway, thereby inhibiting the transcriptional expression of key genes involved in de novo adipogenesis, thus achieving the effect of reducing body fat content in fish.

[0007] This invention provides a method and application for reducing body fat content in fish using androgen receptor agonists, including:

[0008] By enhancing the activity of androgen receptors in the androgen signaling pathway in fish and inhibiting the transcriptional expression of key genes for de novo liposynthesis, fish with reduced liposynthesis can be obtained.

[0009] As a further improvement of the present invention, a method for enhancing the activity of androgen receptors in the androgen signaling pathway of fish is to ingest an androgen receptor agonist in fish.

[0010] As a further improvement of the present invention, the fish ingest the androgen receptor agonist by means of food, injection, or bath.

[0011] As a further improvement of the present invention, the concentration of the androgen receptor agonist during the medicated bath is 50-200 nM.

[0012] As a further improvement of the present invention, the androgen receptor agonist is BMS-564929.

[0013] As a further improvement of the present invention, the key genes for de novo fat synthesis include acaca, fasn, and scd.

[0014] As a further improvement of the present invention, the fish include freshwater farmed fish.

[0015] To achieve the above objectives, the present invention also provides the use of androgen receptor agonists in feeds or drugs for reducing body fat content in fish.

[0016] As a further improvement of the present invention, the body fat includes visceral fat.

[0017] This invention also provides the application of androgen receptor agonists in inhibiting the expression of key genes involved in de novo adipose synthesis.

[0018] The beneficial effects of this invention are:

[0019] The method for reducing body fat content in fish provided by this invention utilizes androgen receptor agonists to enhance the activity of androgen receptors in the androgen signaling pathway of fish. This inhibits the transcriptional expression of key genes involved in de novo fat synthesis, resulting in fish with reduced fat synthesis and thus achieving the effect of lowering body fat content. Based on the method provided by this invention, fish welfare can be improved, fish meat quality can be enhanced, thereby promoting the sustainable development of fisheries and environmental protection. It is also of great significance for fish disease prevention and control, and is key to promoting a healthier and more efficient development of fisheries. While reducing body fat content in fish, the method provided by this invention also expands the application scope of androgen receptor agonists, enabling them to be used as feed or drugs for regulating body fat content in fish. Attached Figure Description

[0020] Figure 1This is a schematic diagram illustrating the regulatory mechanism of the method for reducing body fat content in fish provided by the present invention.

[0021] Figure 2 Nile red staining images of male zebrafish from Example 1 and Comparative Example 1.

[0022] Figure 3 This is a quantitative statistical chart showing the relative fluorescence area of ​​Nile Red staining in male zebrafish from Example 1 and Comparative Example 1.

[0023] Figure 4 This is a comparison chart of the body fat content of male zebrafish in Example 1 and Comparative Example 1.

[0024] Figure 5 This is a comparison diagram showing the expression analysis of de novo liver fat synthesis genes in male zebrafish from Example 1 and Comparative Example 1. Detailed Implementation

[0025] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be described in detail below with reference to the accompanying drawings and specific embodiments.

[0026] It should also be noted that, in order to avoid obscuring the present invention with unnecessary details, only the structures and / or processing steps closely related to the present invention are shown in the accompanying drawings, while other details that are not closely related to the present invention are omitted.

[0027] Additionally, it should be noted that the terms “comprising,” “including,” or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0028] This invention provides a method and application for reducing body fat content in fish using androgen receptor agonists, including:

[0029] By enhancing the activity of androgen receptors in the androgen signaling pathway in fish and inhibiting the transcriptional expression of key genes for de novo liposynthesis, fish with reduced liposynthesis can be obtained.

[0030] One method to enhance the activity of androgen receptors in the androgen signaling pathway in fish is to administer an androgen receptor agonist to the fish. The androgen receptor agonist is BMS-564929. The key genes for de novo lipid synthesis include acaca, fasn, and scd.

[0031] Through the above methods, the present invention can utilize the androgen receptor agonist BMS-564929 to enhance the activity of androgen receptors in the androgen signaling pathway, thereby inhibiting the transcriptional expression of key genes (acaca, fasn, and scd) in de novo fat synthesis, and thus reducing the body fat content of fish.

[0032] Specifically, the fish ingest the androgen receptor agonist via one of the following methods: ingestion, injection, or medicated bath. Preferably, the concentration of the androgen receptor agonist during the medicated bath is 50–200 nM.

[0033] In some embodiments of the present invention, the fish used include freshwater cultured fish.

[0034] The present invention also provides the use of androgen receptor agonists in feeds or drugs for reducing body fat content in fish.

[0035] The body fat mentioned here includes visceral fat.

[0036] This invention also provides the application of androgen receptor agonists in inhibiting the expression of key genes involved in de novo adipose synthesis.

[0037] The following detailed description, in conjunction with specific embodiments, illustrates a method and application of the present invention for reducing body fat content in fish using androgen receptor agonists.

[0038] Example 1

[0039] This embodiment provides a method and application for reducing body fat content in fish using an androgen receptor agonist: The androgen receptor agonist BMS-564929 is prepared into a 200 nM bath, and male zebrafish are placed in this bath for 30 days. This results in fish with reduced fat synthesis, thus lowering the body fat content. For comparison, male zebrafish were also raised in water for 30 days without BMS-564929, with the same rearing environment and feed conditions as in Example 1.

[0040] The schematic diagram of the regulatory mechanism of the androgen receptor agonist BMS-564929 on body fat content in fish is shown below. Figure 1 As shown. By Figure 1 It can be seen that androgen receptor agonists can enhance the activity of androgen receptors in the androgen signaling pathway, thereby inhibiting the transcriptional expression of key genes for de novo lipid synthesis (acaca, fasn, and scd), thus reducing the body fat content of fish.

[0041] Comparative Example 1

[0042] In this comparative example, male zebrafish were kept in water for 30 days. The rearing environment and feed conditions during this period were the same as in Example 1. The only difference from Example 1 was that the androgen receptor agonist BMS-564929 was not used in this comparative example.

[0043] To verify the actual effectiveness of the method provided by this invention, the neutral fatty dye Nile Red was used to stain male zebrafish treated with the androgen receptor agonist BMS-564929 in Example 1 and male zebrafish not treated with the androgen receptor agonist BMS-564929 in Comparative Example 1. The results were then analyzed. Figures 2-4 As shown.

[0044] Depend on Figures 2-4 It can be seen that treating zebrafish with the androgen receptor agonist BMS-564929 via bath can reduce the content of visceral adipose tissue in zebrafish (see details). Figures 2-3 ) and body fat percentage (see details) Figure 4 This indicates that the method provided in Example 1 can effectively reduce the body fat content of zebrafish, and the effect on reducing visceral fat is more significant, with a reduction of more than 80%.

[0045] The expression of liver fat de novo synthesis genes (acaca, fasn, and scd) in male zebrafish treated with the androgen receptor agonist BMS-564929 in Example 1 and in male zebrafish not treated with the androgen receptor agonist BMS-564929 in Comparative Example 1 was detected using real-time quantitative PCR. The results are as follows: Figure 5 As shown.

[0046] Depend on Figure 5 It can be seen that the use of the androgen receptor agonist BMS-564929 can effectively inhibit the expression of the liver fat de novo synthesis genes acaca, fasn and scd, with the inhibitory effect on scd being the most significant. This effectively inhibits the synthesis of fat in zebrafish, reduces visceral fat accumulation, and lowers the body fat content of fish, which is of great significance for the prevention and control of fish diseases caused by high fat content.

[0047] In summary, this invention provides a method and application for reducing body fat content in fish using androgen receptor agonists, relating to the field of fish endocrinology. This invention enhances the activity of androgen receptors in the androgen signaling pathway in fish, inhibiting the transcriptional expression of key genes involved in de novo fat synthesis, thereby obtaining fish with reduced fat synthesis and achieving the effect of reducing body fat content. Specifically, the method for enhancing the activity of androgen receptors in the androgen signaling pathway in fish involves administering an androgen receptor agonist to the fish. Through this method, this invention can effectively intervene and regulate the body fat content of fish using androgen receptor agonists, which is beneficial for improving fish meat quality, preventing diseases induced by excessive fat accumulation in fish, and promoting the healthy development of fisheries. The method provided by this invention, while reducing the body fat content of fish, also expands the application scope of androgen receptor agonists, enabling their use as feed or drugs for regulating body fat content in fish.

[0048] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. The application of the androgen receptor agonist BMS-564929 in inhibiting the transcriptional expression of key genes acaca, fasn, and scd in hepatic de novo fat synthesis, characterized in that, Fish were given the androgen receptor agonist BMS-564929 via a medicated bath at a concentration of 50–200 nM. The androgen receptor agonist enhances the activity of androgen receptors in the androgen signaling pathway, thereby inhibiting the transcriptional expression of key genes for de novo hepatic fat synthesis, namely acaca, fasn, and scd, thus reducing the body fat content of the fish.

2. The application of the androgen receptor agonist BMS-564929 according to claim 1 in inhibiting the transcriptional expression of key genes acaca, fasn, and scd in hepatic de novo fat synthesis, characterized in that: The fish mentioned include freshwater farmed fish.

Images